Acute Coronary Syndromes Compendium

Global Perspective on Acute Coronary Syndrome

A Burden on the Young and Poor

Rajesh Vedanthan, Benjamin Seligman, Valentin Fuster
https://doi.org/10.1161/CIRCRESAHA.114.302782
Circulation Research. 2014;114:1959-1975
Originally published June 5, 2014

This article has a correction. Please see:

Jump to

Abstract

Ischemic heart disease (IHD) is the greatest single cause of mortality and loss of disability-adjusted life years worldwide, and a substantial portion of this burden falls on low- and middle-income countries (LMICs). Deaths from IHD and acute coronary syndrome (ACS) occur, on average, at younger ages in LMICs than in high-income countries, often at economically productive ages, and likewise frequently affect the poor within LMICs. Although data about ACS in LMICs are limited, there is a growing literature in this area and the research gaps are being steadily filled. In high-income countries, decades of investigation into the risk factors for ACS and development of behavioral programs, medications, interventional procedures, and guidelines have provided us with the tools to prevent and treat events. Although similar tools can be, and in fact have been, implemented in many LMICs, challenges remain in the development and implementation of cardiovascular health promotion activities across the entire life course, as well as in access to treatment for ACS and IHD. Intersectoral policy initiatives and global coordination are critical elements of ACS and IHD control strategies. Addressing the hurdles and scaling successful health promotion, clinical and policy efforts in LMICs are necessary to adequately address the global burden of ACS and IHD.

Introduction

Ischemic heart disease (IHD) is the greatest single cause of mortality and loss of disability-adjusted life years (DALYs) worldwide, accounting for roughly 7 million deaths and 129 million DALYs annually.1,2 Cardiovascular disease exerts a significant economic toll, accounting for one third of a projected $47 trillion in economic losses to noncommunicable diseases (NCDs) for the next 20 years.3 Although high-income countries (HICs) continue to deal with significant IHD mortality, nearly two thirds of all IHD DALYs and more than half of deaths occur in low- and middle-income countries (LMICs). Many of these countries have experienced transformational economic growth and lifestyle changes during the past several decades that have increased the prevalence of IHD risk factors and rates of mortality.4–8 Understanding this change, how it compares with past experience in HICs, and available measures to stem the global tide of IHD mortality make up the research and action frontier about acute coronary syndrome (ACS) and IHD in LMICs.

The epidemiological transition provides a useful framework for understanding the rise of IHD in LMICs (Figure 1).9,10 The epidemiological transition posits that populations initially start with low life expectancies with mortality primarily driven by infections, undernutrition, and illness and injury related to childbirth and early childhood (age of pestilence and famine). As sanitation and agriculture improve, these causes of death gradually recede (age of receding pandemics) until NCDs, particularly IHD and cancers, dominate the causes of death (age of degenerative and man-made diseases). Still later, as cancers and IHD become preventable or controllable, the burden of these diseases shift to older ages (age of delayed degenerative diseases).11 A fifth stage has also been proposed, in light of recent adverse trends in physical activity and diet—an age of obesity and inactivity.12

Figure 1.
Figure 1.

The epidemiological transition in the United States, which was already well underway by 1900. Figure reprinted with permission from Armstrong et al.13

Rapid urbanization, mechanization of transport, and increasingly sedentary jobs in LMICs have led to an acceleration and overlap between the stages of the epidemiological transition.14–17 Although infections, undernutrition, and maternal/child mortality are still important, they are no longer dominant causes of death in many LMICs: IHD is now 1 of the top 5 causes of death in all regions of the world except sub-Saharan Africa. Even in sub-Saharan Africa, cardiovascular disease is the leading cause of death among individuals >30 years.18 Overall, the numbers of deaths and DALYs attributable to IHD have risen since 1990.19,20 This acceleration in the rise of NCDs without a similar reduction of infectious disease burden has led to a challenging double burden of disease in many countries.14,21,22 In addition, the age-standardized mortality rates from IHD are higher in many LMICs than in HICs, thus indicating more individuals are dying at a younger age from IHD in LMICs (Figure 2).20 Although much of the IHD burden in LMICs is occurring as those regions and individuals enter higher economic strata, there remains a substantial health and economic burden on the poorer segments of LMIC societies resulting from IHD and related NCDs.23–25 In addition, given population growth in LMICs, the absolute numbers of individuals with premature IHD are substantial even as global, age-standardized IHD mortality rates have declined.19,20

Figure 2.
Figure 2.

Mortality rates from ischemic heart disease per 100 000 in 2010 by country, ages 15 to 49, men (top) and women (bottom). Data derived from 2012 Global Burden of Disease.26

There has also been a dramatic rise in several IHD risk factors. Obesity and overweight prevalence have been increasing in many LMICs,6,27–29 more than tripling between 1975 and 1997 among children in Brazil from 4.1% to 13.9%.27 The age-standardized prevalence of obesity and overweight increased from 30.8% in 1980 to 46.4% in 2008, with half of the increase occurring after 2000.29 Globally, mean body mass index has been increasing in nearly every region of the world (Figure 3). Other biological risk factors have demonstrated geographic and temporal variability. Comprehensive analyses of systolic blood pressure have revealed increases in sub-Saharan Africa and South/Southeast Asia, relatively little change in Latin America, and substantial decreases in HICs (Figure 4).4 In contrast, mean serum cholesterol levels have tended to decline in several regions of the world, although at varying rates5: HICs and the former Soviet Union have experienced notable declines, South Asia has seen much more modest declines, whereas Latin America and the Middle East did not change and levels actually rose in East Asia (Figure 5).

Figure 3.
Figure 3.

Age-standardized mean body mass index (BMI) by sex and region. Green indicates high-income countries; black, East Asia/Pacific; red, Eastern Europe/Central Asia; dark blue, Latin America/Caribbean; light blue, Middle East/North Africa; purple, South Asia; and yellow, sub-Saharan Africa. Data derived from Global Burden of Metabolic Risk Factors of Chronic Diseases215 and World Population Prospects, 2012 Revision.216

Figure 4.
Figure 4.

Age-standardized mean systolic blood pressure (SBP) by sex and region. Green indicates high-income countries; black, East Asia/Pacific; red, Eastern Europe/Central Asia; dark blue, Latin America/Caribbean; light blue, Middle East/North Africa; purple, South Asia; and yellow, sub-Saharan Africa. Data derived from Global Burden of Metabolic Risk Factors of Chronic Diseases215 and World Population Prospects, 2012 Revision.216

Figure 5.
Figure 5.

Age-standardized mean total cholesterol (TC) by sex and region. Green indicates high-income countries; black, East Asia/Pacific; red, Eastern Europe/Central Asia; dark blue, Latin America/Caribbean; light blue, Middle East/North Africa; purple, South Asia; and yellow, sub-Saharan Africa. Data derived from Global Burden of Metabolic Risk Factors of Chronic Diseases215 and World Population Prospects, 2012 Revision.216

Underpinning the rises in biological risk factors have been rises in behavioral risk factors. Although recent reports suggest that global smoking prevalence has declined since 1980, the total number of smokers has increased to nearly 1 billion people in 201230 and remains common in many LMICs31 despite some notable successes.32–34 There is also significant geographic variability in smoking rates, with certain areas (Russia, Eastern Europe, Central Asia, China, Southeast Asia, North Africa, and parts of South America) characterized by high age-standardized prevalence of daily smoking (Figure 6). Consumption of other unhealthy products, such as sugary beverages, processed foods, and alcohol, has increased.35 Likewise, large numbers of adults around the world have low levels of physical activity; although there are significant regional variations, several LMICs have physical inactivity levels that rival those of HICs (Figure 7).36 From the most recent Global Burden of Disease estimates, the top 10 risk factors contributing to mortality and DALYs in LMICs were all behavioral or biological risks for NCDs (Figure 8).37

Figure 6.
Figure 6.

Age-standardized prevalence of smoking as percent of population: men (top) and women (bottom). Data derived from Ng et al.30

Figure 7.
Figure 7.

Age-adjusted percent of adults who are physically inactive: men (A) and women (B). Figure reprinted with permission from Hallal et al.36

Figure 8.
Figure 8.

Percentage of total deaths (top) and disability-adjusted life years (DALYs; bottom) in low- and middle-income countries for men (left) and women (right) of all ages attributable to different categories of risk factors. Data derived from 2012 Global Burden of Disease.26 PM indicates particulate matter. Red shades refer to communicable, maternal, neonatal, and nutritional disorders, blue shades refer to noncommunicable diseases, and green shades refer to injuries. Different shades of each color refer to different specific causes.

In this review, we aim to describe the global perspective about ACS. However, given the limited, though growing, body of data about ACS outside of HICs, we use IHD as a surrogate for ACS when data for ACS are not available. Thus, we examine in detail the trends of IHD burden in HICs, compare and contrast the recent experience in LMICs, discuss the history of ACS treatment and prevention in HICs, and outline steps for addressing ACS in LMICs.

Rise and Fall of IHD Mortality in HICs

Current HICs struggled with growing rates of ACS and associated mortality during the mid-20th century.38–40 However, HICs have experienced significant declines in mortality rates from all cardiovascular conditions since the 1960s.41–43 Both treatment and prevention have contributed to the observed reductions in IHD mortality in HICs (Table 1).44–46 Treatment includes improved care for ACS, as well as chronic medical management of IHD. Preventive efforts include both behavioral and pharmacological initiatives.

View this table:
Table 1.

Declines in Coronary Heart Disease Mortality in Selected High- and Middle-Income Countries, With Attributable Portions Owing to Risk Factor Changes (Prevention) and Treatment

Advances in the acute management of ACS include many celebrated achievements in intensive care-related and interventional approaches to cardiovascular medicine: the creation of the coronary care unit55; the introduction of streptokinase56 and later thrombolytic drugs57; and the development of coronary artery catheterization, balloon angioplasty,58 and surgical revascularization.43,59 These advances made it possible, rather than to simply observe the natural history of ACS complications, to intervene and attempt to modify the natural course of illness. Use of emergency medical systems, initially established for trauma care and to transport patients with suspected ACS, has also helped reduce the time between symptom onset and intervention, despite underutilization by many individuals who have acute events.60–62 These interventions have changed acute management from passivity and impotence to activity and intervention, with the potential to avert premature death and disability.

Additional success in IHD treatment is reflected in the multidimensional approach to medical management of IHD and secondary prevention of further events. This foundation of optimal medical therapy includes a combination of medications that is started acutely and maintained post-ACS: aspirin, β-blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers, and statins. The evidence for their use has been established throughout several decades, including the ISIS (International Studies of Infarct Survival) series of trials for β-blockers,63 aspirin (alongside streptokinase),64 and ACE inhibitors.65 Long-term evidence for these medications has been built up in meta-analyses of numerous trials.66–69 Evidence for statins began to emerge with low-dose therapies in the 4S (Scandinavian Simvastatin Survival Study) and CARE (Cholesterol and Recurrent Events) trials,70,71 whereas later trials showed the increased benefits of more intensive lipid lowering.72–74

Improvements in primordial and primary prevention were driven first by an understanding of the underlying risks of cardiovascular disease, particularly through the Framingham Heart Study75,76 and the Seven Countries Study.77 These and related studies78 helped define the roles of tobacco use, blood pressure, and cholesterol as risk factors for IHD, challenging beliefs about the benign nature of some risk factors and making what had seemed an inevitable consequence of aging become something that could potentially be prevented.79,80

Building on the evidence of risk, intervention studies changed the practice of prevention. Pharmacological intervention was pioneered by the Veterans Administration Cooperative Studies,81 showing reductions in morbidity and mortality in individuals treated for hypertension. For cholesterol, the Lipid Research Clinics trial provided early evidence that cholesterol reduction using medication could reduce incidence of IHD.82 Likewise, dietary and behavior change were first validated with the Oslo Study Group trial,83 whereas the North Karelia Project and later the Five Community Study provided evidence of the effects of public health approaches.84,85 The modern-day guidelines for cholesterol, blood pressure, and lifestyle modification are the result of decades-long efforts to accommodate the latest evidence from rigorous clinical trials into best practice recommendations.86–90 These efforts, in combination with regulatory initiatives to ban trans fats91,92 and global tobacco control,93 have made substantial impact, with corresponding decreases in blood pressure, lipid levels, and tobacco use over time.94–98

However, there are still major gaps in the midst of these overall improvements and also concerning trends with respect to overweight, obesity, and diabetes mellitus. Body mass index has increased worldwide virtually without exception.6 Within the United States, the past decade has seen a rise in the prevalence of obesity among adult men and women belonging to racial or ethnic minorities.99 There have also been declines in physical activity and increases in caloric intake.100,101 In terms of overall cardiovascular health, <1% of adults in the United States were found to have ideal cardiovascular health, with high prevalence noted for poor diet (>90%) and high body mass index (>50%).102 Projections of these trends suggest that, without intervention, poor health behaviors will continue to be highly prevalent with increases in diabetes mellitus prevalence and subsequent cardiovascular complications.103

ACS and IHD Burden in LMICs

In some respects, the ACS and IHD situation in LMICs today is more similar to that of HICs in decades past. In particular, the burden of ACS is not solely on the rich nor on the elderly but also on the poor and working age.104 According to the most recent Global Burden of Disease study, the median age of death from IHD among men was a decade younger in LMICs than in HICs in 2010 (Figure 9). This may be because of earlier onset of ACS and IHD, as well as shorter survival after ACS. The available results from the OASIS-1 (Organization to Assess Strategies in Acute Ischemic Syndromes) and OASIS-2 registries105 and epidemiological studies in India106–108 suggest that earlier age for first ACS in LMICs is a major contributing factor. Registry data from many other LMICs also support the assertion that ACS often occurs at younger ages than in HICs109–119: strikingly, a registry from the United Arab Emirates reported a mean age of 50.8 years.120 Earlier age for first ACS is likely because of earlier acquisition of adverse health behaviors and IHD risk factors10,107,121,122 in the current context of economic development and globalization. One notable exception to this overall trend is the experience of an ACS registry in Thailand.123,124

Figure 9.
Figure 9.

Age distribution of men (top) and women (bottom) of ischemic heart disease (IHD); deaths in 2010 among countries classified as high-income countries (HICs) vs low- and middle-income countries (LMICs). Data derived from Lozano et al.1

The treatment and outcomes of ACS in LMICs are variable but often suboptimal (Table 2).125 Observational studies do suggest that, to a large extent, the in-hospital treatment of ACS in LMICs includes the use of aspirin, ACE inhibitors, and β-blockers.105,108,126–128 The ACCESS (Acute Coronary Events – a Multinational Survey of Current Management Strategies) study, a prospective observational registry of patients hospitalized for ACS between 2007 and 2008 in 19 LMICs, found that aspirin and lipid-lowering therapies were each given to >90% of patients, whereas uptake of β-blockers and ACE inhibitors was at 78% and 68%, respectively.126 However, comparison of countries participating in the OASIS registries found lower use of heparin in LMICs than in HICs, whereas the ACCESS investigators found that only 39% of patients presenting with ST-elevation myocardial infarction received fibrinolysis. In addition, there also exist substantive within-country differences in the management of ACS, as is the case in India.125

View this table:
Table 2.

Summary of Published Literature About ACS in Low- and Middle-Income Countries

Furthermore, continuation of these medications following discharge is poor: investigators from the Prospective Urban Rural Epidemiology study found that among individuals with previous cardiovascular events, nearly 70% of those in lower-middle-income countries and 80% of those in low-income countries were on no medication for secondary prevention.131 They also found lower uptake of lifestyle changes following cardiovascular events in LMICs than in HICs, with 75% of individuals in HICs quitting smoking versus 42% in lower-middle-income countries and 38% in low-income countries.132 Likewise, the World Health Organization (WHO) PREMISE (Prevention of Recurrences of Myocardial Infarction and Stroke) survey of patients with coronary artery disease in LMICs found that although aspirin was in widespread use and that >75% of respondents were aware of behavioral risk factors for cardiovascular disease, a majority engaged in <30 minutes of physical activity weekly and less than one third were taking statins.133 Administrative data among patients with IHD from Andhra Pradesh were similarly discouraging, with only 15.6% receiving aspirin and 6.0% on cholesterol-lowering medications.115 Evidence for the quality of clinical outcomes is conflicting. The OASIS registries found comparable mortality rates across participating countries after age adjustment. By contrast, a review of randomized trials of ST-elevation myocardial infarction treatments found that trial sites in LMICs had higher mortality rates than their counterparts in HICs, which the authors explained by increased numbers of high-risk patients.135 Further clarification of the quality of ACS outcomes in LMICs is needed.

In addition, the impact of ACS and IHD on household livelihood is substantial in LMICs. As noted above, in LMICs, these events occur at younger ages, often during peak economic productivity. Households experience a double burden both from the great expense of treating ACS and from the loss of income of the affected individual. In general, NCD expenditures increased as a proportion of out-of-pocket healthcare costs in India from 1995 to 2004 and were found to have greater odds of carrying catastrophic health expenditure than did communicable diseases among hospitalized patients.136 Additional work confirms that individuals with NCDs have higher health expenditures than individuals with communicable diseases25,137 and that households with an individual with an NCD are more likely to face catastrophic health expenditures.137,138 In a multicountry survey of individuals hospitalized for cardiovascular conditions, more than half of the hospitalized individuals reported catastrophic health expenditures or distress financing.24 Survival with disability, such as diminished exercise capacity that may arise from heart failure related to IHD, may further burden households’ stretched finances. Testimonies from individuals living with NCDs are notable for their desire not to be a burden on their families.139

The socioeconomic gradient of ACS in LMICs is also striking. Even in low-income countries, these are diseases that inflict a large burden on the poor. For instance, in South Africa, poorer districts of Cape Town had higher rates of mortality from NCDs than did wealthier districts.140 In the SAGE (Study on Global Ageing and Adult Health) surveys of health in 6 middle-income countries, hypertension prevalence was high, between 30% and 36%, across all income strata.134 A survey of 1600 rural villages in India found higher prevalence of tobacco and alcohol use and lower intake of fruits and vegetables among poorer respondents.141 Likewise, >70% of individuals with suspected myocardial infarction in the Indian CREATE (Treatment and Outcomes of Acute Coronary Syndromes in India) registry were classified as poor or lower middle income.130 Furthermore, higher socioeconomic status was found to be protective against risk of myocardial infarction in India.142 Although there are likely geographic variations, the poor of sub-Saharan Africa face considerable burden from infectious and nutritional diseases, it is clear that the poor in LMICs do indeed experience a substantial burden of ACS and IHD.

Stemming the Tide: Cardiovascular Health Promotion Throughout the Life Course

Despite the challenges of addressing ACS in LMICs, the time is now to implement interventions aimed at cardiovascular health promotion throughout the life course.143,144 Health promotion activities directed at all ages, access to essential medicines,145 improved quality of healthcare services to manage risk factors and treat acute events, and intersectoral policy initiatives146 can, in combination, prevent millions of premature deaths in the coming decades. A wide array of interventions are cost-effective and scalable in LMICs,147 and an analysis by the WHO of intervention packages for specific risk factors suggests that implementation can be done at low cost per person.148

There is increasing evidence that IHD risk factors have their origins in early childhood.149–154 Health promotion interventions targeted at young children may have beneficial impacts on both short-term health behaviors and long-term risk factors.155–160 Effective school-based interventions are those that include the family and that center on realistic intermediate objectives, such as changes in attitude, knowledge, dietary patterns, or levels of physical activity, as early control measures that improve cardiovascular health.161 Critical to the success of these interventions is community engagement, cultural relevance and appropriateness, optimization of the school environment, and involvement of the family.162–164 Programs that have been implemented successfully in LMICs155,156 can be reproduced in other low-resource settings.165,166

Addressing dietary risk factors can be cost-effective. An analysis of salt-reduction measures estimated conservatively that a 15% reduction in salt intake could save 2.4 million lives for 10 years at a cost of $0.50 per person,167 in-line with other findings suggesting that salt reduction at processing stages of food production can be cost-effective.168 Likewise, reductions in saturated and trans fats by controlling use in food processing can be cost-effective, estimated at $40 per DALY in Latin America when focusing on trans fats.147,168 By focusing on processing sources, these interventions are readily scalable, costing <$0.01 per person.148

Physical activity remains a challenge to evaluate; however, the WHO estimates that a public awareness campaign could be implemented at $0.038 per person. One major challenge to physical activity has been urbanization, which has produced mechanized transportation environments that discourage physical activity.169 However, there are clear interventions for addressing lifestyle and the built environment,170 and WHO guidelines on physical activity provide a clear way forward.171 Efforts in Brazil and Colombia to improve physical activity in cities are 1 example of success in this area,172 although there is substantial room to improve policies promoting healthy diets and physical activity.173

Effective interventions are also well known to reduce tobacco use, many of which are provisions of the Framework Convention on Tobacco Control: restrictions on advertising, packaging, marketing to minors, use in public spaces, and taxes.93 Extensive analysis has suggested that these interventions produce robust results, with particularly strong response to taxation in developing countries.174 Furthermore, these are highly cost-effective, from $3 to $42 for a 33% tax rate on tobacco to $55 to $761 per DALY in LMICs for nicotine replacement therapy.175 The WHO’s best buys for global health estimate that a package of interventions including taxation, packaging and advertising restrictions, counteradvertising, and use restrictions could be implemented for ≈$0.11 per person.148 However, there have been several challenges to ratification and implementation of the Framework Convention.176 One major challenge has been the push for voluntary, nation-level approaches rather than a coordinated global treaty.177–181 After passage of the Framework Convention, it has been documented that the tobacco industry has attempted to undermine this treaty by subverting its provisions,182–184 has pursued lawsuits against signatories that have implemented treaty provisions,185 and has been noted by the WHO as actively preventing implementation of treaty provisions that aim to keep the tobacco industry out of public health policy making.186 Robust and transparent governance is necessary to overcome these challenges.187

Treatment of ACS and IHD

Approaches to treatment can be divided into 2 categories: interventions for acute events and interventions for primary and secondary prevention. According to the Disease Control Priorities Project,18 streptokinase was the most cost-effective reperfusion therapy at cost $634 to $734 per DALY. This strategy, however, became more expensive per DALY saved as time to treatment increased. Alteplase and coronary artery bypass surgery were both >$10 000 per DALY. The use of aspirin, β-blockers, and ACE inhibitors was found to be cost-effective and in some circumstances cost-saving. To date, there remains a dearth of research on the cost-effectiveness of reperfusion therapies in LMICs.147 In-hospital use of other evidence-based management, such as anticoagulation, antiplatelet medications, and statins, can be improved with the implementation of systems-level approaches, such as reminder, checklists, case management, and educational materials.129

For primary and secondary prevention, a multidrug regimen consisting of a β-blocker or calcium channel blocker, an ACE inhibitor, aspirin, and a statin was found to be cost-effective.188 On the basis of the need for a multidrug regimen for pharmacotherapy, efforts have been made at creating a polypill that brings together these various medications and makes adherence simpler.189–192 A meta-analysis of trials found that, compared with placebo, a polypill did reduce blood pressure and serum lipids.193 The polypill strategy is generally thought to be associated with improved adherence related to fewer number of pills to be consumed on a daily basis. However, the data about adherence of a cardiovascular polypill are mixed. The meta-analysis concluded that the polypill strategy had lower rates of adherence, with 20% of polypill recipients discontinuing use versus 14% of those on placebo or monotherapy, although the trials included were highly heterogenous.193 On the contrary, the more recent UMPIRE (Use of a Multi-drug Pill in Reducing Cardiovascular Events) study found much higher rates of adherence for those receiving a polypill versus usual care.194 If the challenges in developing a polypill are overcome, it is possible that this, too, will be a cost-effective and essential tool for prevention.195,196

Medication access remains a significant challenge in LMICs.197,198 Data from India indicate that poor patients are less likely to receive evidence-based in-hospital treatments, such as revascularization, thrombolytics, and lipid-lowering drugs.130 Surveys of medication use suggest low levels of uptake of therapy for primary and secondary prevention of IHD.131,133 Affordability is an important reason as to why uptake is so low: IHD medication may cost more than an individual’s daily income.25,147 As these medications must be taken daily for many years, cost is a primary concern in ensuring that the majority of those in need have the ability to access appropriate care. Innovative strategies to optimize the healthcare workforce to manage IHD and ACS,199 as well as to improve access to essential medicines,145 are required.

Integrated Health Service Delivery, Intersectoral Policy, and Global Coordination

Healthcare delivery systems in LMICs would benefit from a comprehensive approach that integrates services related to NCDs and communicable diseases such as human immunodeficiency virus.200 Beyond the above-described interventions for specifically ACS and IHD, overall cardiovascular care in LMICs would benefit from strengthening health systems, improving quality of care, optimizing human resources for health, establishing secure supply chains of drugs and technology, and promoting equitable access to care. Instead of vertical, disease-specific programs, a diagonal approach in which cardiovascular-related healthcare delivery is integrated into a comprehensive approach to health systems strengthening will likely yield superior results.201–205 To maximize the effectiveness of health sector-specific interventions, they should be implemented in the context of broader population-level policy changes and community-level programs.

Thus, the remaining intervention necessary, perhaps underlying all of the above interventions, is comprehensive intersectoral policy dedicated to NCDs in general.146,206,207 The roots of IHD risk are not contained solely within the health sector, and the entire spectrum of stakeholders is required to commit to policies and programs that will create the conditions that improve cardiovascular health. This would include, at a minimum, representation from the health, education, infrastructure, transportation, urban planning, trade, and finance sectors. In addition, productive partnerships among government, private sector, and civil society are possible and required.

Finally, although the large global burden of NCDs is well established, funding from donors does not match this reality. In 2010, although NCDs collectively accounted for 49.8% of DALY burden of disease, they received only 2.3% of development assistance for health.208 Within the WHO’s own budget, only 12% was allocated to NCDs for the 2006 to 2007 fiscal year, out of line with disease burden.209 Analysis of spending by donors broadly, including private philanthropies such as the Gates Foundation, showed a similarly skewed allocation, with human immunodeficiency virus/acquired immune deficiency syndrome accounting for the largest portion of health spending, far in excess of its DALY-measured burden compared with NCDs and with other communicable diseases.210 Another study reported spending of $0.78 per DALY for NCDs versus $23.90 per DALY for HIV, tuberculosis, and malaria.211 Although funding for NCDs has increased during the past decade,208,211 allocation of funding that is more in-line with actual disease burden may aid the achievement of an array of global health goals. The prospects for improving this balance of funding are challenging and require greater participation among aid recipient countries and alignment of United Nations institutions around NCD goals.212 At the country level, health insurance and payment systems ideally should ensure equitable access to both in-hospital treatment of ACS and long-term outpatient access to medications and rehabilitative services.213 In addition, public–private partnerships and other innovative financing mechanisms will be required.

Conclusions

Similar to the situation in HICs decades ago, LMICs today are well into a transition toward increasing morbidity and mortality from ACS and IHD. However, there are features that distinguish the patterns of ACS in LMICs from HICs. First, the death toll falls more heavily on younger, productive ages in LMICs than in HICs, with mortality rates among adults aged 15 to 49 in some LMICs nearly double that in HICs. Second, the rate of the epidemiological transition to increased burden from IHD has happened more rapidly in LMICs today than in HICs in the past. In addition, ACS and IHD are not diseases confined to the privileged classes; rather, there is a significant burden that also falls hard on the low-income strata in LMICs, who often are unable to afford the costs of medical therapy for primary or secondary prevention of IHD, let alone the expensive treatments for ACS that have helped make acute events more survivable in HICs. Together, these help explain the substantial economic burden that is anticipated from ACS and IHD if no action is taken.

Despite the immense burden, the global community is aided by new knowledge and discoveries made during the past half century. We continue to evolve more efficient and efficacious treatment strategies for ACS, ranging from rapid transport of patients to hospitals via emergency medical systems, to timely reperfusion, through to long-term cardiac rehabilitation, optimal medical therapy, and risk factor control. We understand what the underlying risk factors for ACS are and how to prevent them through cardiovascular health promotion activities throughout the life course, appropriate therapeutic strategies, and intersectoral policy. The scientific challenge is primarily in translating this existing knowledge to new settings. In addition, the growing body of ACS literature from LMICs highlights the importance of local, national, and regional registries as important sources of information about current practices and inspiration for improvement and change.125,214

The critical task is implementation: the tools that we have need to be materialized. This involves engaging in health promotion activities in early childhood, ensuring access to essential medicines to treat and prevent ACS, developing resource- and context-specific clinical guidelines, implementing laws and regulations to protect the public’s health from harmful products, planning the growth of cities to promote healthy behavior, and support from donor countries and international organizations to match the scale of the global burden of ACS, IHD, and other NCDs. We are well equipped to confront this challenge so long as our will meets it.

Acknowledgment

We thank Claire Hutchinson for editorial assistance.

Sources of Funding

R. Vedanthan is supported by the Fogarty International Center of the National Institutes of Health under award number K01 TW 009218-03. B. Seligman is supported by the Stanford Interdisciplinary Graduate Fellowship and partly by National Institute on Aging grant R24AG0393345. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures

None.

Footnotes

  • In April 2014, the average time from submission to first decision for all original research papers submitted to Circulation Research was 14.38 days.

  • Circulation Research Compendium on Acute Coronary Syndromes

    Acute Coronary Syndromes: Pathology, Diagnosis, Genetics, Prevention, and Treatment

    Mechanisms of Plaque Formation and Rupture

    Inflammation and Its Resolution as Determinants of Acute Coronary Syndromes

    Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome

    Genetics of Coronary Artery Disease

    Imaging Plaques to Predict and Better Manage Patients With Acute Coronary Events

    Reperfusion Strategies in Acute Coronary Syndromes

    Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes

    Nonantithrombotic Medical Options in Acute Coronary Syndromes: Old Agents and New Lines on the Horizon

    Global Perspective on Acute Coronary Syndrome: A Burden on the Young and Poor

    Guest Editors: Valentin Fuster and Jason Kovacic

  • Nonstandard Abbreviations and Acronyms
    ACE
    angiotensin-converting enzyme
    ACS
    acute coronary syndrome
    DALY
    disability-adjusted life year
    HICs
    high-income countries
    IHD
    ischemic heart disease
    LMICs
    low- and middle-income countries
    NCDs
    noncommunicable diseases
    WHO
    World Health Organization

  • Received February 25, 2014.
  • Revision received May 7, 2014.
  • Accepted May 7, 2014.

References

  1. 1.↵
    1. Lozano R,
    2. Naghavi M,
    3. Foreman K,
    4. et al
    . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Murray CJ,
    2. Vos T,
    3. Lozano R,
    4. et al
    . Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bloom DE,
    2. Cafiero ET,
    3. Jané-Llopis E,
    4. et al
    . The Global Economic Burden of Non-communicable Diseases. World Economic Forum: Geneva; 2011.
  4. 4.↵
    1. Danaei G,
    2. Finucane MM,
    3. Lin JK,
    4. Singh GM,
    5. Paciorek CJ,
    6. Cowan MJ,
    7. Farzadfar F,
    8. Stevens GA,
    9. Lim SS,
    10. Riley LM,
    11. Ezzati M
    ; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet. 2011;377:568–577.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Farzadfar F,
    2. Finucane MM,
    3. Danaei G,
    4. Pelizzari PM,
    5. Cowan MJ,
    6. Paciorek CJ,
    7. Singh GM,
    8. Lin JK,
    9. Stevens GA,
    10. Riley LM,
    11. Ezzati M
    ; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol). National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants. Lancet. 2011;377:578–586.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Finucane MM,
    2. Stevens GA,
    3. Cowan MJ,
    4. Danaei G,
    5. Lin JK,
    6. Paciorek CJ,
    7. Singh GM,
    8. Gutierrez HR,
    9. Lu Y,
    10. Bahalim AN,
    11. Farzadfar F,
    12. Riley LM,
    13. Ezzati M
    ; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet. 2011;377:557–567.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Rivera JA,
    2. Barquera S,
    3. González-Cossío T,
    4. Olaiz G,
    5. Sepúlveda J
    . Nutrition transition in Mexico and in other Latin American countries. Nutr Rev. 2004;62:S149–S157.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Shetty PS
    . Nutrition transition in India. Public Health Nutr. 2002;5:175–182.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Omran AR
    . The epidemiologic transition. A theory of the epidemiology of population change. Milbank Mem Fund Q. 1971;49:509–538.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Yusuf S,
    2. Reddy S,
    3. Ounpuu S,
    4. Anand S
    . Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–2753.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Olshansky SJ,
    2. Ault AB
    . The fourth stage of the epidemiologic transition: the age of delayed degenerative diseases. Milbank Q. 1986;64:355–391.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Gaziano JM
    . Fifth phase of the epidemiologic transition: the age of obesity and inactivity. JAMA. 2010;303:275–276.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Armstrong GL,
    2. Conn LA,
    3. Pinner RW
    . Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281:61–66.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Frenk J,
    2. Bobadilla JL,
    3. Sepúlveda J,
    4. Cervantes ML
    . Health transition in middle-income countries: new challenges for health care. Health Policy Plan. 1989;4:29–39.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Boutayeb A
    . The double burden of communicable and non-communicable diseases in developing countries. Trans R Soc Trop Med Hyg. 2006;100:191–199.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Remais JV,
    2. Zeng G,
    3. Li G,
    4. Tian L,
    5. Engelgau MM
    . Convergence of non-communicable and infectious diseases in low- and middle-income countries. Int J Epidemiol. 2013;42:221–227.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Bygbjerg IC
    . Double burden of noncommunicable and infectious diseases in developing countries. Science. 2012;337:1499–1501.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Jamison DT,
    2. Breman JG,
    3. Measham AR
    1. Gaziano TA,
    2. Reddy KS,
    3. Paccaud F,
    4. Horton S,
    5. Chaturvedi V
    . Cardiovascular disease. In: Jamison DT, Breman JG, Measham AR, et al. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006:645–662.
  19. 19.↵
    1. Moran AE,
    2. Forouzanfar MH,
    3. Roth GA,
    4. Mensah GA,
    5. Ezzati M,
    6. Flaxman A,
    7. Murray CJ,
    8. Naghavi M
    . The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation. 2014;129:1493–1501.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Moran AE,
    2. Forouzanfar MH,
    3. Roth GA,
    4. Mensah GA,
    5. Ezzati M,
    6. Murray CJ,
    7. Naghavi M
    . Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the global burden of disease 2010 study. Circulation. 2014;129:1483–1492.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Yach D,
    2. Hawkes C,
    3. Gould CL,
    4. Hofman KJ
    . The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Ali MK,
    2. Rabadán-Diehl C,
    3. Flanigan J,
    4. Blanchard C,
    5. Narayan KM,
    6. Engelgau M
    . Systems and capacity to address noncommunicable diseases in low- and middle-income countries. Sci Transl Med. 2013;5:181cm4.
    OpenUrlFREE Full Text
  23. 23.↵
    1. Ezzati M,
    2. Vander Hoorn S,
    3. Lawes CM,
    4. Leach R,
    5. James WP,
    6. Lopez AD,
    7. Rodgers A,
    8. Murray CJ
    . Rethinking the “diseases of affluence” paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med. 2005;2:e133.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Huffman MD,
    2. Rao KD,
    3. Pichon-Riviere A,
    4. et al
    . A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011;6:e20821.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Binnendijk E,
    2. Koren R,
    3. Dror DM
    . Can the rural poor in India afford to treat non-communicable diseases. Trop Med Int Health. 2012;17:1376–1385.
    OpenUrlCrossRef
  26. 26.↵
    Institute for Health Metrics and Evaluation. GBD Compare. 2013. http://vizhub.healthdata.org/gbd-compare. Accessed on March 14, 2014.
  27. 27.↵
    1. Wang Y,
    2. Monteiro C,
    3. Popkin BM
    . Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. Am J Clin Nutr. 2002;75:971–977.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Wang H,
    2. Du S,
    3. Zhai F,
    4. Popkin BM
    . Trends in the distribution of body mass index among Chinese adults, aged 20-45 years (1989-2000). Int J Obes (Lond). 2007;31:272–278.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Stevens GA,
    2. Singh GM,
    3. Lu Y,
    4. Danaei G,
    5. Lin JK,
    6. Finucane MM,
    7. Bahalim AN,
    8. McIntire RK,
    9. Gutierrez HR,
    10. Cowan M,
    11. Paciorek CJ,
    12. Farzadfar F,
    13. Riley L,
    14. Ezzati M
    ; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index). National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012;10:22.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Ng M,
    2. Freeman MK,
    3. Fleming TD,
    4. Robinson M,
    5. Dwyer-Lindgren L,
    6. Thomson B,
    7. Wollum A,
    8. Sanman E,
    9. Wulf S,
    10. Lopez AD,
    11. Murray CJ,
    12. Gakidou E
    . Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311:183–192.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Giovino GA,
    2. Mirza SA,
    3. Samet JM,
    4. Gupta PC,
    5. Jarvis MJ,
    6. Bhala N,
    7. Peto R,
    8. Zatonski W,
    9. Hsia J,
    10. Morton J,
    11. Palipudi KM,
    12. Asma S
    ; GATS Collaborative Group. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet. 2012;380:668–679.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Monteiro CA,
    2. Cavalcante TM,
    3. Moura EC,
    4. Claro RM,
    5. Szwarcwald CL
    . Population-based evidence of a strong decline in the prevalence of smokers in Brazil (1989-2003). Bull World Health Organ. 2007;85:527–534.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Peer N,
    2. Bradshaw D,
    3. Laubscher R,
    4. Steyn K
    . Trends in adult tobacco use from two South African demographic and health surveys conducted in 1998 and 2003. S Afr Med J. 2009;99:744–749.
    OpenUrlPubMed
  34. 34.↵
    1. Jha P,
    2. Peto R
    . Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370:60–68.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Stuckler D,
    2. McKee M,
    3. Ebrahim S,
    4. Basu S
    . Manufacturing epidemics: the role of global producers in increased consumption of unhealthy commodities including processed foods, alcohol, and tobacco. PLoS Med. 2012;9:e1001235.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Hallal PC,
    2. Andersen LB,
    3. Bull FC,
    4. Guthold R,
    5. Haskell W,
    6. Ekelund U
    ; Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012;380:247–257.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Lim SS,
    2. Vos T,
    3. Flaxman AD,
    4. et al
    . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Puffer RR,
    2. Verhoestraete LJ
    . Mortality from cardiovascular diseases in various countries, with special reference to atherosclerotic heart disease: a preliminary analysis. Bull World Health Organ. 1958;19:315–324.
    OpenUrlPubMed
  39. 39.↵
    1. Campbell M
    . The main cause of increased death rate from disease of the heart: 1920 to 1959. Br Med J. 1963;2:712–717.
    OpenUrlFREE Full Text
  40. 40.↵
    1. Hechter HH,
    2. Borhani NO
    . Mortality and geographic distribution of arteriosclerotic heart disease. Public Health Rep. 1965;80:11–24.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Levi F,
    2. Lucchini F,
    3. Negri E,
    4. La Vecchia C
    . Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002;88:119–124.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Rosamond WD,
    2. Chambless LE,
    3. Heiss G,
    4. Mosley TH,
    5. Coresh J,
    6. Whitsel E,
    7. Wagenknecht L,
    8. Ni H,
    9. Folsom AR
    . Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008. Circulation. 2012;125:1848–1857.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Nabel EG,
    2. Braunwald E
    . A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366:54–63.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Ford ES,
    2. Capewell S
    . Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health. 2011;32:5–22.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Tunstall-Pedoe H,
    2. Vanuzzo D,
    3. Hobbs M,
    4. Mähönen M,
    5. Cepaitis Z,
    6. Kuulasmaa K,
    7. Keil U
    . Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000;355:688–700.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Kuulasmaa K,
    2. Tunstall-Pedoe H,
    3. Dobson A,
    4. Fortmann S,
    5. Sans S,
    6. Tolonen H,
    7. Evans A,
    8. Ferrario M,
    9. Tuomilehto J
    . Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675–687.
    OpenUrlCrossRefPubMed
  47. 47.
    1. Unal B,
    2. Critchley JA,
    3. Capewell S
    . Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101–1107.
    OpenUrlAbstract/FREE Full Text
  48. 48.
    1. Laatikainen T,
    2. Critchley J,
    3. Vartiainen E,
    4. Salomaa V,
    5. Ketonen M,
    6. Capewell S
    . Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol. 2005;162:764–773.
    OpenUrlAbstract/FREE Full Text
  49. 49.
    1. Bennett K,
    2. Kabir Z,
    3. Unal B,
    4. Shelley E,
    5. Critchley J,
    6. Perry I,
    7. Feely J,
    8. Capewell S
    . Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. J Epidemiol Community Health. 2006;60:322–327.
    OpenUrlAbstract/FREE Full Text
  50. 50.
    1. Palmieri L,
    2. Bennett K,
    3. Giampaoli S,
    4. Capewell S
    . Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health. 2010;100:684–692.
    OpenUrlCrossRefPubMed
  51. 51.
    1. Capewell S,
    2. Beaglehole R,
    3. Seddon M,
    4. McMurray J
    . Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation. 2000;102:1511–1516.
    OpenUrlAbstract/FREE Full Text
  52. 52.
    1. Capewell S,
    2. Morrison CE,
    3. McMurray JJ
    . Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999;81:380–386.
    OpenUrlAbstract/FREE Full Text
  53. 53.
    1. Björck L,
    2. Rosengren A,
    3. Bennett K,
    4. Lappas G,
    5. Capewell S
    . Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J. 2009;30:1046–1056.
    OpenUrlAbstract/FREE Full Text
  54. 54.
    1. Ford ES,
    2. Ajani UA,
    3. Croft JB,
    4. Critchley JA,
    5. Labarthe DR,
    6. Kottke TE,
    7. Giles WH,
    8. Capewell S
    . Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388–2398.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Julian DG
    . The evolution of the coronary care unit. Cardiovasc Res. 2001;51:621–624.
    OpenUrlFREE Full Text
  56. 56.↵
    Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;327:397–402.
    OpenUrl
  57. 57.↵
    The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71–75.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Grüntzig AR,
    2. Senning Å,
    3. Siegenthaler WE
    . Nonoperative dilatation of coronary-artery stenosis. N Engl J Med. 1979;301:61–68.
    OpenUrlCrossRefPubMed
  59. 59.↵
    1. Malach M,
    2. Imperato PJ
    . Acute myocardial infarction and acute coronary syndrome: then and now (1950-2005). Prev Cardiol. 2006;9:228–234.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. So DY,
    2. Ha AC,
    3. Turek MA,
    4. Maloney JP,
    5. Higginson LA,
    6. Davies RF,
    7. Ryan SC,
    8. Le May MR
    . Comparison of mortality patterns in patients with ST-elevation myocardial infarction arriving by emergency medical services versus self-transport (from the prospective Ottawa Hospital STEMI Registry). Am J Cardiol. 2006;97:458–461.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Mathews R,
    2. Peterson ED,
    3. Li S,
    4. Roe MT,
    5. Glickman SW,
    6. Wiviott SD,
    7. Saucedo JF,
    8. Antman EM,
    9. Jacobs AK,
    10. Wang TY
    . Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. Circulation. 2011;124:154–163.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    1. Tan LL,
    2. Wong HB,
    3. Poh CL,
    4. Chan MY,
    5. Seow SC,
    6. Yeo TC,
    7. Teo SG,
    8. Ooi SB,
    9. Tan HC,
    10. Lee CH
    . Utilisation of emergency medical service among Singapore patients presenting with ST-segment elevation myocardial infarction: prevalence and impact on ischaemic time. Intern Med J. 2011;41:809–814.
    OpenUrlCrossRefPubMed
  63. 63.↵
    First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986;2:57–66.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Baigent C,
    2. Collins R,
    3. Appleby P,
    4. Parish S,
    5. Sleight P,
    6. Peto R
    . ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337–1343.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. Lancet. 1995;345:669–685.
    OpenUrlCrossRefPubMed
  66. 66.↵
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Freemantle N,
    2. Cleland J,
    3. Young P,
    4. Mason J,
    5. Harrison J
    . Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730–1737.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation. 1998;97:2202–2212.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Sacks FM,
    2. Pfeffer MA,
    3. Moye LA,
    4. Rouleau JL,
    5. Rutherford JD,
    6. Cole TG,
    7. Brown L,
    8. Warnica JW,
    9. Arnold JMO,
    10. Wun C-C,
    11. Davis BR,
    12. Braunwald E
    . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Schwartz GG
    . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 2001;285:1711.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Cannon CP,
    2. Braunwald E,
    3. McCabe CH,
    4. Rader DJ,
    5. Rouleau JL,
    6. Belder R,
    7. Joyal SV,
    8. Hill KA,
    9. Pfeffer MA,
    10. Skene AM
    ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Pedersen TR,
    2. Faergeman O,
    3. Kastelein JJ,
    4. Olsson AG,
    5. Tikkanen MJ,
    6. Holme I,
    7. Larsen ML,
    8. Bendiksen FS,
    9. Lindahl C,
    10. Szarek M,
    11. Tsai J
    ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Kannel WB,
    2. Schwartz MJ,
    3. McNamara PM
    . Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest. 1969;56:43–52.
    OpenUrlCrossRefPubMed
  76. 76.↵
    1. Kannel WB,
    2. Castelli WP,
    3. Gordon T,
    4. McNamara PM
    . Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74:1–12.
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Farchi G,
    2. Capocaccia R,
    3. Verdecchia A,
    4. Menotti A,
    5. Keys A
    . Risk factors changes and coronary heart disease in an observational study. Int J Epidemiol. 1981;10:31–40.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Kromhout D,
    2. Menotti A,
    3. Kesteloot H,
    4. Sans S
    . Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation. 2002;105:893–898.
    OpenUrlFREE Full Text
  79. 79.↵
    1. Kotchen TA
    . Historical trends and milestones in hypertension research: a model of the process of translational research. Hypertension. 2011;58:522–538.
    OpenUrlCrossRef
  80. 80.↵
    1. Moser M
    . Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich). 2006;8:15–20; quiz 39.
    OpenUrlCrossRefPubMed
  81. 81.↵
    Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028.
  82. 82.↵
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA. 1984;251:351.
  83. 83.↵
    1. Hjermann I,
    2. Holme I,
    3. Byre KV,
    4. Leren P
    . Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981;318:1303–1310.
    OpenUrlCrossRef
  84. 84.↵
    1. Puska P,
    2. Nissinen A,
    3. Tuomilehto J,
    4. Salonen JT,
    5. Koskela K,
    6. McAlister A,
    7. Kottke TE,
    8. Maccoby N,
    9. Farquhar JW
    . The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia project. Annu Rev Public Health. 1985;6:147–193.
    OpenUrlCrossRefPubMed
  85. 85.↵
    1. Farquhar JW
    . Effects of communitywide education on cardiovascular disease risk factors. JAMA. 1990;264:359.
  86. 86.↵
    1. James PA,
    2. Oparil S,
    3. Carter BL,
    4. et al
    . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–520.
    OpenUrlCrossRefPubMed
  87. 87.↵
    1. Eckel RH,
    2. Jakicic JM,
    3. Ard JD,
    4. et al
    . 2013 AHA/ACC Guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
  88. 88.↵
    1. Stone NJ,
    2. Robinson J,
    3. Lichtenstein AH,
    4. et al
    . 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
  89. 89.↵
    National Institute for Health and Care Excellence. CG67 Lipid Modification. 2010. London: National Institute for Health and Care Excellence.
  90. 90.↵
    National Institute for Health and Care Excellence. CG127 Hypertension. 2011. London: National Institute for Health and Care Excellence.
  91. 91.↵
    1. McGreevy P
    . State bans trans fats. The Los Angeles Times. Published July 26, 2008. Available at: http://articles.latimes.com/2008/jul/26/local/me-transfat26. Accessed February 11, 2014.
  92. 92.↵
    Food Preparation and Food Establishments. Section 81.08 Foods containing artificial trans fat. New York City. http://www.nyc.gov/html/doh/downloads/pdf/public/notice-intention-hc-art81-08.pdf. Accessed March 14, 2014.
  93. 93.↵
    Conference of the Parties to the WHO FCTC. WHO Framework Convention on Tobacco Control. 2003. http://www.who.int/fctc/text_download/en. Accessed March 14, 2014.
  94. 94.↵
    1. Evans A,
    2. Tolonen H,
    3. Hense HW,
    4. Ferrario M,
    5. Sans S,
    6. Kuulasmaa K
    ; WHO MONICA Project. Trends in coronary risk factors in the WHO MONICA project. Int J Epidemiol. 2001;30(suppl 1):S35–S40.
    OpenUrlFREE Full Text
  95. 95.↵
    1. Gregg EW,
    2. Cheng YJ,
    3. Cadwell BL,
    4. Imperatore G,
    5. Williams DE,
    6. Flegal KM,
    7. Narayan KM,
    8. Williamson DF
    . Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293:1868–1874.
    OpenUrlCrossRefPubMed
  96. 96.↵
    1. Egan BM,
    2. Zhao Y,
    3. Axon RN
    . US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043–2050.
    OpenUrlCrossRefPubMed
  97. 97.↵
    1. Cohen JD,
    2. Cziraky MJ,
    3. Cai Q,
    4. Wallace A,
    5. Wasser T,
    6. Crouse JR,
    7. Jacobson TA
    . 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol. 2010;106:969–975.
    OpenUrlCrossRefPubMed
  98. 98.↵
    1. Garrett BE,
    2. Dube SR,
    3. Trosclair A,
    4. Caraballo RS,
    5. Pechacek TF
    . Cigarette smoking—United States, 1965–2008. MMWR. 2011;60:109–113.
    OpenUrlPubMed
  99. 99.↵
    1. Flegal KM,
    2. Carroll MD,
    3. Kit BK,
    4. Ogden CL
    . Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491–497.
    OpenUrlCrossRefPubMed
  100. 100.↵
    1. King DE,
    2. Mainous AG 3rd.,
    3. Carnemolla M,
    4. Everett CJ
    . Adherence to healthy lifestyle habits in US adults, 1988-2006. Am J Med. 2009;122:528–534.
    OpenUrlCrossRefPubMed
  101. 101.↵
    1. Ford ES,
    2. Dietz WH
    . Trends in energy intake among adults in the United States: findings from NHANES. Am J Clin Nutr. 2013;97:848–853.
    OpenUrlAbstract/FREE Full Text
  102. 102.↵
    1. Shay CM,
    2. Ning H,
    3. Allen NB,
    4. Carnethon MR,
    5. Chiuve SE,
    6. Greenlund KJ,
    7. Daviglus ML,
    8. Lloyd-Jones DM
    . Status of cardiovascular health in US adults: prevalence estimates from the National Health and Nutrition Examination Surveys (NHANES) 2003-2008. Circulation. 2012;125:45–56.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Huffman MD,
    2. Capewell S,
    3. Ning H,
    4. Shay CM,
    5. Ford ES,
    6. Lloyd-Jones DM
    . Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation. 2012;125:2595–2602.
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    1. Leeder S,
    2. Raymond S,
    3. Greenberg H,
    4. Liu H,
    5. Esson K
    A Race Against Time: the Challenge of Cardiovascular Disease in Developing Economies. Columbia University: New York; 2004.
  105. 105.↵
    1. Prabhakaran D,
    2. Yusuf S,
    3. Mehta S,
    4. et al
    . Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart J. 2005;57:217–225.
    OpenUrlPubMed
  106. 106.↵
    1. Srivastava A,
    2. Mohanty SK
    . Age and sex pattern of cardiovascular mortality, hospitalisation and associated cost in India. PLoS One. 2013;8:e62134.
    OpenUrlCrossRef
  107. 107.↵
    1. Joshi P,
    2. Islam S,
    3. Pais P,
    4. Reddy S,
    5. Dorairaj P,
    6. Kazmi K,
    7. Pandey MR,
    8. Haque S,
    9. Mendis S,
    10. Rangarajan S,
    11. Yusuf S
    . Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297:286–294.
    OpenUrlCrossRefPubMed
  108. 108.↵
    1. Mohanan PP,
    2. Mathew R,
    3. Harikrishnan S,
    4. Krishnan MN,
    5. Zachariah G,
    6. Joseph J,
    7. Eapen K,
    8. Abraham M,
    9. Menon J,
    10. Thomas M,
    11. Jacob S,
    12. Huffman MD,
    13. Prabhakaran D
    ; Kerala ACS Registry Investigators. Presentation, management, and outcomes of 25 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur Heart J. 2013;34:121–129.
    OpenUrlAbstract/FREE Full Text
  109. 109.↵
    1. Juárez-Herrera Ú,
    2. Jerjes-Sánchez C
    ; RENASICA II Investigators. Risk factors, therapeutic approaches, and in-hospital outcomes in Mexicans with ST-elevation acute myocardial infarction: the RENASICA II multicenter registry. Clin Cardiol. 2013;36:241–248.
    OpenUrlCrossRef
  110. 110.↵
    1. Piegas LS,
    2. Avezum A,
    3. Guimarães HP,
    4. Muniz AJ,
    5. Reis HJ,
    6. Santos ES,
    7. Knobel M,
    8. Souza RD
    . Acute coronary syndrome behavior: results of a Brazilian registry. Arq Bras Cardiol. 2013;100:502–510.
    OpenUrl
  111. 111.↵
    1. Shavadia J,
    2. Yonga G,
    3. Otieno H
    . A prospective review of acute coronary syndromes in an urban hospital in sub-Saharan Africa. Cardiovasc J Afr. 2012;23:318–321.
    OpenUrlCrossRefPubMed
  112. 112.↵
    1. Demirkan B,
    2. Ege MR,
    3. Doğan P,
    4. İpek EG,
    5. Güray U,
    6. Güray Y
    . Factors influencing the use of ambulance among patients with acute coronary syndrome: results of two centers in Turkey. Anadolu Kardiyol Derg. 2013;13:516–522.
    OpenUrl
  113. 113.↵
    1. Gao R,
    2. Patel A,
    3. Gao W,
    4. Hu D,
    5. Huang D,
    6. Kong L,
    7. Qi W,
    8. Wu Y,
    9. Yang Y,
    10. Harris P,
    11. Algert C,
    12. Groenestein P,
    13. Turnbull F
    ; CPACS Investigators. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart. 2008;94:554–560.
    OpenUrlAbstract/FREE Full Text
  114. 114.↵
    1. Saidi O,
    2. Ben Mansour N,
    3. O’Flaherty M,
    4. Capewell S,
    5. Critchley JA,
    6. Ben Romdhane H
    . Analyzing recent coronary heart disease mortality trends in Tunisia between 1997 and 2009. PLoS One. 2013;8:e63202.
    OpenUrlCrossRef
  115. 115.↵
    1. Joshi R,
    2. Chow CK,
    3. Raju PK,
    4. Raju R,
    5. Reddy KS,
    6. Macmahon S,
    7. Lopez AD,
    8. Neal B
    . Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation. 2009;119:1950–1955.
    OpenUrlAbstract/FREE Full Text
  116. 116.↵
    1. Mattos LAPE,
    2. Berwanger O,
    3. dos Santos ES,
    4. Reis HJL,
    5. Romano ER,
    6. Petriz JLF,
    7. Sousa ACS,
    8. Neuenschwander FC,
    9. Guimarães JI,
    10. de Andrade JP
    . Desfechos clínicos aos 30 dias do registro brasileiro das síndromes coronárias agudas (ACCEPT). Arq Bras Cardiol. 2013;100:6–13.
    OpenUrlCrossRef
  117. 117.↵
    1. Puymirat E,
    2. Battler A,
    3. Birkhead J,
    4. et al
    ; EHS 2009 Snapshot Participants. Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. Eur Heart J Acute Cardiovasc Care. 2013;2:359–370.
    OpenUrlAbstract/FREE Full Text
  118. 118.↵
    1. Song XT,
    2. Chen YD,
    3. Pan WQ,
    4. Lü SZ
    ; CRACE Investigators. Gender based differences in patients with acute coronary syndrome: findings from Chinese Registry of Acute Coronary Events (CRACE). Chin Med J (Engl). 2007;120:1063–1067.
    OpenUrlPubMed
  119. 119.↵
    1. Ahmed E,
    2. Alhabib KF,
    3. El-Menyar A,
    4. Asaad N,
    5. Sulaiman K,
    6. Hersi A,
    7. Almahmeed W,
    8. Alsheikh-Ali AA,
    9. Amin H,
    10. Al-Motarreb A,
    11. Al Saif S,
    12. Singh R,
    13. Al-Lawati J,
    14. Al Suwaidi J
    . Age and clinical outcomes in patients presenting with acute coronary syndromes. J Cardiovasc Dis Res. 2013;4:134–139.
    OpenUrlCrossRefPubMed
  120. 120.↵
    1. Yusufali AM,
    2. AlMahmeed W,
    3. Tabatabai S,
    4. Rao K,
    5. Binbrek A
    . Acute coronary syndrome registry from four large centres in United Arab Emirates (UAE-ACS Registry). Heart Asia. 2010;2:118–121.
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    1. Reddy KS
    . Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutr. 2002;5:231–237.
    OpenUrlCrossRefPubMed
  122. 122.↵
    1. Critchley J,
    2. Liu J,
    3. Zhao D,
    4. Wei W,
    5. Capewell S
    . Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation. 2004;110:1236–1244.
    OpenUrlAbstract/FREE Full Text
  123. 123.↵
    1. Srimahachota S,
    2. Kanjanavanit R,
    3. Boonyaratavej S,
    4. Boonsom W,
    5. Veerakul G,
    6. Tresukosol D
    ; TACSR Group. Demographic, management practices and in-hospital outcomes of Thai Acute Coronary Syndrome Registry (TACSR): the difference from the Western world. J Med Assoc Thai. 2007;90(suppl 1):1–11.
    OpenUrlPubMed
  124. 124.↵
    1. Srimahachota S,
    2. Boonyaratavej S,
    3. Kanjanavanit R,
    4. Sritara P,
    5. Krittayaphong R,
    6. Kunjara-Na-ayudhya R,
    7. Tatsanavivat P
    ; TRACS Group. Thai Registry in Acute Coronary Syndrome (TRACS)–an extension of Thai Acute Coronary Syndrome registry (TACS) group: lower in-hospital but still high mortality at one-year. J Med Assoc Thai. 2012;95:508–518.
    OpenUrlPubMed
  125. 125.↵
    1. Karthikeyan G,
    2. Xavier D,
    3. Prabhakaran D,
    4. Pais P
    . Perspectives on the management of coronary artery disease in India. Heart. 2007;93:1334–1338.
    OpenUrlAbstract/FREE Full Text
  126. 126.↵
    ACCESS Investigators. Management of acute coronary syndromes in developing countries: acute coronary events—a multinational Survey of current management Strategies. Am Heart J. 2011;162:852–859.e22.
    OpenUrlCrossRefPubMed
  127. 127.↵
    1. Huffman MD,
    2. Prabhakaran D,
    3. Abraham AK,
    4. Krishnan MN,
    5. Nambiar AC,
    6. Mohanan PP
    ; Kerala Acute Coronary Syndrome Registry Investigators. Optimal in-hospital and discharge medical therapy in acute coronary syndromes in Kerala: results from the Kerala acute coronary syndrome registry. Circ Cardiovasc Qual Outcomes. 2013;6:436–443.
    OpenUrlAbstract/FREE Full Text
  128. 128.↵
    1. Pagidipati NJ,
    2. Huffman MD,
    3. Jeemon P,
    4. et al
    . Association between gender, process of care measures, and outcomes in ACS in India: results from the detection and management of coronary heart disease (DEMAT) registry. PLoS One. 2013;8:e62061.
    OpenUrlCrossRef
  129. 129.↵
    1. Berwanger O,
    2. Guimarães HP,
    3. Laranjeira LN,
    4. et al
    ; Bridge-ACS Investigators. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial. JAMA. 2012;307:2041–2049.
    OpenUrlCrossRefPubMed
  130. 130.↵
    1. Xavier D,
    2. Pais P,
    3. Devereaux PJ,
    4. Xie C,
    5. Prabhakaran D,
    6. Reddy KS,
    7. Gupta R,
    8. Joshi P,
    9. Kerkar P,
    10. Thanikachalam S,
    11. Haridas KK,
    12. Jaison TM,
    13. Naik S,
    14. Maity AK,
    15. Yusuf S
    ; CREATE Registry Investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008;371:1435–1442.
    OpenUrlCrossRefPubMed
  131. 131.↵
    1. Yusuf S,
    2. Islam S,
    3. Chow CK,
    4. et al
    ; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231–1243.
    OpenUrlCrossRefPubMed
  132. 132.↵
    1. Teo K,
    2. Lear S,
    3. Islam S,
    4. et al
    ; PURE Investigators. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: the Prospective Urban Rural Epidemiology (PURE) study. JAMA. 2013;309:1613–1621.
    OpenUrlCrossRefPubMed
  133. 133.↵
    1. Mendis S,
    2. Abegunde D,
    3. Yusuf S,
    4. Ebrahim S,
    5. Shaper G,
    6. Ghannem H,
    7. Shengelia B
    . WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ. 2005;83:820–829.
    OpenUrlPubMed
  134. 134.↵
    1. Basu S,
    2. Millett C
    . Social epidemiology of hypertension in middle-income countries: determinants of prevalence, diagnosis, treatment, and control in the WHO SAGE study. Hypertension. 2013;62:18–26.
    OpenUrlCrossRef
  135. 135.↵
    1. Orlandini A,
    2. Díaz R,
    3. Wojdyla D,
    4. Pieper K,
    5. Van de Werf F,
    6. Granger CB,
    7. Harrington RA,
    8. Boersma E,
    9. Califf RM,
    10. Armstrong P,
    11. White H,
    12. Simes J,
    13. Paolasso E
    . Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006;27:527–533.
    OpenUrlAbstract/FREE Full Text
  136. 136.↵
    1. Engelgau MM,
    2. Karan A,
    3. Mahal A
    . The economic impact of non-communicable diseases on households in India. Global Health. 2012;8:9.
    OpenUrlCrossRefPubMed
  137. 137.↵
    1. Kankeu HT,
    2. Saksena P,
    3. Xu K,
    4. Evans DB
    . The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst. 2013;11:31.
    OpenUrlCrossRef
  138. 138.↵
    1. Rahman MM,
    2. Gilmour S,
    3. Saito E,
    4. Sultana P,
    5. Shibuya K
    . Health-related financial catastrophe, inequality and chronic illness in Bangladesh. PLoS One. 2013;8:e56873.
    OpenUrlCrossRef
  139. 139.↵
    World Health Organization. Preventing Chronic Diseases: A Vital Investment. Geneva: World Health Organization; 2005.
  140. 140.↵
    1. Mayosi BM,
    2. Flisher AJ,
    3. Lalloo UG,
    4. Sitas F,
    5. Tollman SM,
    6. Bradshaw D
    . The burden of non-communicable diseases in South Africa. Lancet. 2009;374:934–947.
    OpenUrlCrossRefPubMed
  141. 141.↵
    1. Kinra S,
    2. Bowen LJ,
    3. Lyngdoh T,
    4. Prabhakaran D,
    5. Reddy KS,
    6. Ramakrishnan L,
    7. Gupta R,
    8. Bharathi AV,
    9. Vaz M,
    10. Kurpad AV,
    11. Smith GD,
    12. Ben-Shlomo Y,
    13. Ebrahim S
    . Sociodemographic patterning of non-communicable disease risk factors in rural India: a cross sectional study. BMJ. 2010;341:c4974.
    OpenUrlAbstract/FREE Full Text
  142. 142.↵
    1. Pais P,
    2. Pogue J,
    3. Gerstein H,
    4. Zachariah E,
    5. Savitha D,
    6. Jayprakash S,
    7. Nayak PR,
    8. Yusuf S
    . Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet. 1996;348:358–363.
    OpenUrlCrossRefPubMed
  143. 143.↵
    1. Fuster V,
    2. Kelly BB
    Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, DC: The National Academies Press; 2010.
  144. 144.↵
    1. Fuster V,
    2. Kelly BB,
    3. Vedanthan R
    . Promoting global cardiovascular health: moving forward. Circulation. 2011;123:1671–1678.
    OpenUrlFREE Full Text
  145. 145.↵
    1. Kishore SP,
    2. Vedanthan R,
    3. Fuster V
    . Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. J Am Coll Cardiol. 2011;57:1980–1987.
    OpenUrlCrossRefPubMed
  146. 146.↵
    1. Fuster V,
    2. Kelly BB,
    3. Vedanthan R
    . Global cardiovascular health: urgent need for an intersectoral approach. J Am Coll Cardiol. 2011;58:1208–1210.
    OpenUrlCrossRefPubMed
  147. 147.↵
    1. Gaziano TA,
    2. Pagidipati N
    . Scaling up chronic disease prevention interventions in lower- and middle-income countries. Annu Rev Public Health. 2013;34:317–335.
    OpenUrlCrossRef
  148. 148.↵
    World Health Organization. Scaling Up Action Against Noncommunicable Diseases: How Much Will It Cost? Geneva: World Health Organization. 2011.
  149. 149.↵
    1. Biro FM,
    2. Wien M
    . Childhood obesity and adult morbidities. Am J Clin Nutr. 2010;91:1499S–1505S.
    OpenUrlAbstract/FREE Full Text
  150. 150.↵
    1. Agras WS,
    2. Hammer LD,
    3. McNicholas F,
    4. Kraemer HC
    . Risk factors for childhood overweight: a prospective study from birth to 9.5 years. J Pediatr. 2004;145:20–25.
    OpenUrlCrossRefPubMed
  151. 151.↵
    1. Bjørge T,
    2. Engeland A,
    3. Tverdal A,
    4. Smith GD
    . Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. Am J Epidemiol. 2008;168:30–37.
    OpenUrlAbstract/FREE Full Text
  152. 152.↵
    1. Freedman DS,
    2. Khan LK,
    3. Serdula MK,
    4. Dietz WH,
    5. Srinivasan SR,
    6. Berenson GS
    . The relation of childhood BMI to adult adiposity: the Bogalusa Heart Study. Pediatrics. 2005;115:22–27.
    OpenUrlAbstract/FREE Full Text
  153. 153.↵
    1. Bibbins-Domingo K,
    2. Coxson P,
    3. Pletcher MJ,
    4. Lightwood J,
    5. Goldman L
    . Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357:2371–2379.
    OpenUrlCrossRefPubMed
  154. 154.↵
    1. Cunningham SA,
    2. Kramer MR,
    3. Narayan KM
    . Incidence of childhood obesity in the United States. N Engl J Med. 2014;370:403–411.
    OpenUrlCrossRefPubMed
  155. 155.↵
    1. Céspedes J,
    2. Briceño G,
    3. Farkouh ME,
    4. Vedanthan R,
    5. Baxter J,
    6. Leal M,
    7. Boffetta P,
    8. Woodward M,
    9. Hunn M,
    10. Dennis R,
    11. Fuster V
    . Targeting preschool children to promote cardiovascular health: cluster randomized trial. Am J Med. 2013;126:27–35.e3.
    OpenUrlCrossRefPubMed
  156. 156.↵
    1. Céspedes J,
    2. Briceño G,
    3. Farkouh ME,
    4. Vedanthan R,
    5. Baxter J,
    6. Leal M,
    7. Boffetta P,
    8. Hunn M,
    9. Dennis R,
    10. Fuster V
    . Promotion of cardiovascular health in preschool children: 36-month cohort follow-up. Am J Med. 2013;126:1122–1126.
    OpenUrlCrossRef
  157. 157.↵
    1. Draper CE,
    2. de Villiers A,
    3. Lambert EV,
    4. Fourie J,
    5. Hill J,
    6. Dalais L,
    7. Abrahams Z,
    8. Steyn NP
    . HealthKick: a nutrition and physical activity intervention for primary schools in low-income settings. BMC Public Health. 2010;10:398.
    OpenUrlCrossRefPubMed
  158. 158.↵
    1. Foster GD,
    2. Linder B,
    3. Baranowski T,
    4. Cooper DM,
    5. Goldberg L,
    6. Harrell JS,
    7. Kaufman F,
    8. Marcus MD,
    9. Treviño RP,
    10. Hirst K
    . A school-based intervention for diabetes risk reduction. N Engl J Med 2010;363:443–453.
    OpenUrlCrossRefPubMed
  159. 159.↵
    1. Galvez MP,
    2. Hong L,
    3. Choi E,
    4. Liao L,
    5. Godbold J,
    6. Brenner B
    . Childhood obesity and neighborhood food-store availability in an inner-city community. Acad Pediatr. 2009;9:339–343.
    OpenUrlCrossRefPubMed
  160. 160.↵
    1. Ritchie LD,
    2. Sharma S,
    3. Ikeda JP,
    4. Mitchell RA,
    5. Raman A,
    6. Green BS,
    7. Hudes ML,
    8. Fleming SE
    . Taking action together: a YMCA-based protocol to prevent type-2 diabetes in high-BMI inner-city African American children. Trials. 2010;11:60.
    OpenUrlCrossRefPubMed
  161. 161.↵
    1. Birch LL,
    2. Ventura AK
    . Preventing childhood obesity: what works? Int J Obes (Lond). 2009;33(suppl 1):S74–S81.
    OpenUrlPubMed
  162. 162.↵
    Institute of Medicine. Progress in Preventing Childhood Obesity: How Do We Measure Up? Washington, DC: The National Academies Press; 2007.
  163. 163.↵
    US Department of Health and Human Services. Strategic Plan for NIH Obesity Research: a Report of the NIH Obesity Task Force. National Institutes of Health: Bethesda; 2004.
  164. 164.↵
    1. Katz DL,
    2. O’Connell M,
    3. Njike VY,
    4. Yeh MC,
    5. Nawaz H
    . Strategies for the prevention and control of obesity in the school setting: systematic review and meta-analysis. Int J Obes (Lond). 2008;32:1780–1789.
    OpenUrlCrossRefPubMed
  165. 165.↵
    1. Peñalvo JL,
    2. Sotos-Prieto M,
    3. Santos-Beneit G,
    4. Pocock S,
    5. Redondo J,
    6. Fuster V
    . The Program SI! intervention for enhancing a healthy lifestyle in preschoolers: first results from a cluster randomized trial. BMC Public Health. 2013;13:1208.
    OpenUrlCrossRef
  166. 166.↵
    1. Peñalvo JL,
    2. Santos-Beneit G,
    3. Sotos-Prieto M,
    4. Martínez R,
    5. Rodríguez C,
    6. Franco M,
    7. López-Romero P,
    8. Pocock S,
    9. Redondo J,
    10. Fuster V
    . A cluster randomized trial to evaluate the efficacy of a school-based behavioral intervention for health promotion among children aged 3 to 5. BMC Public Health. 2013;13:656.
    OpenUrlCrossRef
  167. 167.↵
    1. Asaria P,
    2. Chisholm D,
    3. Mathers C,
    4. Ezzati M,
    5. Beaglehole R
    . Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–2053.
    OpenUrlCrossRefPubMed
  168. 168.↵
    1. Jamison DT,
    2. Breman JG,
    3. Measham AR
    1. Willett WC,
    2. Koplan JP,
    3. Nugent R,
    4. Dusenbury C,
    5. Puska P,
    6. Gaziano TA
    . Prevention of chronic disease by means of diet and lifestyle changes. In: Jamison DT, Breman JG, Measham AR, et al. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006:833-850.
  169. 169.↵
    1. Smit W,
    2. Hancock T,
    3. Kumaresen J,
    4. Santos-Burgoa C,
    5. Sánchez-Kobashi Meneses R,
    6. Friel S
    . Toward a research and action agenda on urban planning/design and health equity in cities in low and middle-income countries. J Urban Health. 2011;88:875–885.
    OpenUrlCrossRefPubMed
  170. 170.↵
    1. Trowbridge MJ,
    2. Schmid TL
    . Built environment and physical activity promotion: place-based obesity prevention strategies. J Law Med Ethics. 2013;41(suppl 2):46–51.
    OpenUrlCrossRef
  171. 171.↵
    World Health Organization. Global Recommendations on Physical Activity for Health. World Heart Organization: Geneva. 2010.
  172. 172.↵
    1. Díaz Del Castillo A,
    2. Sarmiento OL,
    3. Reis RS,
    4. Brownson RC
    . Translating evidence to policy: urban interventions and physical activity promotion in Bogotá, Colombia and Curitiba, Brazil. Transl Behav Med. 2011;1:350–360.
    OpenUrlCrossRefPubMed
  173. 173.↵
    1. Lachat C,
    2. Otchere S,
    3. Roberfroid D,
    4. Abdulai A,
    5. Seret FM,
    6. Milesevic J,
    7. Xuereb G,
    8. Candeias V,
    9. Kolsteren P
    . Diet and physical activity for the prevention of noncommunicable diseases in low- and middle-income countries: a systematic policy review. PLoS Med. 2013;10:e1001465.
    OpenUrlCrossRefPubMed
  174. 174.↵
    1. Jha P,
    2. Chaloupka FJ
    Tobacco Control in Developing Countries. New York: Oxford University Press; 2000.
  175. 175.↵
    1. Jamison DT,
    2. Breman JG,
    3. Measham AR
    1. Jha P,
    2. Chaloupka FJ,
    3. Moore J,
    4. Gajalakshmi V,
    5. Gupta PC,
    6. Peck R,
    7. Asma S,
    8. Zatonski W
    . Tobacco addiction. In: Jamison DT, Breman JG, Measham AR, et al. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006:869–885.
  176. 176.↵
    1. Piné-Abata H,
    2. McNeill A,
    3. Raw M,
    4. Bitton A,
    5. Rigotti N,
    6. Murray R
    . A survey of tobacco dependence treatment guidelines in 121 countries. Addiction. 2013;108:1470–1475.
    OpenUrlCrossRefPubMed
  177. 177.↵
    1. Mamudu HM,
    2. Hammond R,
    3. Glantz SA
    . Project Cerberus: tobacco industry strategy to create an alternative to the Framework Convention on Tobacco Control. Am J Public Health. 2008;98:1630–1642.
    OpenUrlCrossRefPubMed
  178. 178.↵
    1. Gonzalez M,
    2. Green LW,
    3. Glantz SA
    . Through tobacco industry eyes: civil society and the FCTC process from Philip Morris and British American Tobacco’s perspectives. Tob Control. 2012;21:e1.
    OpenUrlAbstract/FREE Full Text
  179. 179.↵
    1. Bitton A,
    2. Green C,
    3. Colbert J
    . Improving the delivery of global tobacco control. Mt Sinai J Med. 2011;78:382–393.
    OpenUrlCrossRefPubMed
  180. 180.↵
    1. Bitton A,
    2. Raw M,
    3. Richards A,
    4. McNeill A,
    5. Rigotti NA
    . A comparison of four international surveys of tobacco dependence treatment provision: implications for monitoring the Framework Convention on Tobacco Control. Addiction. 2010;105:2184–2191.
    OpenUrlCrossRefPubMed
  181. 181.↵
    1. Weishaar H,
    2. Collin J,
    3. Smith K,
    4. Grüning T,
    5. Mandal S,
    6. Gilmore A
    . Global health governance and the commercial sector: a documentary analysis of tobacco company strategies to influence the WHO framework convention on tobacco control. PLoS Med. 2012;9:e1001249.
    OpenUrlCrossRefPubMed
  182. 182.↵
    1. Crosbie E,
    2. Sebrié EM,
    3. Glantz SA
    . Tobacco industry success in Costa Rica: the importance of FCTC article 5.3. Salud Publica Mex. 2012;54:28–38.
    OpenUrlCrossRefPubMed
  183. 183.↵
    1. Nakkash R,
    2. Lee K
    . The tobacco industry’s thwarting of marketing restrictions and health warnings in Lebanon. Tob Control. 2009;18:310–316.
    OpenUrlAbstract/FREE Full Text
  184. 184.↵
    1. Lee S,
    2. Ling PM,
    3. Glantz SA
    . The vector of the tobacco epidemic: tobacco industry practices in low and middle-income countries. Cancer Causes Control. 2012;23(suppl 1):117–129.
    OpenUrlCrossRefPubMed
  185. 185.↵
    1. Lencucha R
    . Philip Morris versus Uruguay: health governance challenged. Lancet. 2010;376:852–853.
    OpenUrlCrossRefPubMed
  186. 186.↵
    WHO Framework Convention on Tobacco Control Convention Secretariat. 2012 Global Progress Report on Implementation of the WHO Framework Convention on Tobacco Control. World Health Organization: Geneva. 2012.
  187. 187.↵
    1. Smith KE,
    2. Gilmore AB,
    3. Fooks G,
    4. Collin J,
    5. Weishaar H
    . Tobacco industry attempts to undermine Article 5.3 and the “good governance” trap. Tob Control. 2009;18:509–511.
    OpenUrlFREE Full Text
  188. 188.↵
    1. Gaziano TA,
    2. Opie LH,
    3. Weinstein MC
    . Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368:679–686.
    OpenUrlCrossRefPubMed
  189. 189.↵
    1. Lonn E,
    2. Bosch J,
    3. Teo KK,
    4. Pais P,
    5. Xavier D,
    6. Yusuf S
    . The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122:2078–2088.
    OpenUrlFREE Full Text
  190. 190.↵
    1. Sanz G,
    2. Fuster V
    . Prevention: polypills for cardiovascular prevention: a step forward? Nat Rev Cardiol. 2013;10:683–684.
    OpenUrlCrossRef
  191. 191.↵
    1. Sanz G,
    2. Fuster V,
    3. Guzmán L,
    4. Guglietta A,
    5. Arnáiz JA,
    6. Martínez F,
    7. Sarria A,
    8. Roncaglioni MC,
    9. Taubert K
    . The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J. 2011;162:811–817.e1.
    OpenUrlCrossRefPubMed
  192. 192.↵
    1. Sanz G,
    2. Fuster V
    . Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009;6:101–110.
    OpenUrlCrossRefPubMed
  193. 193.↵
    1. Elley CR,
    2. Gupta AK,
    3. Webster R,
    4. Selak V,
    5. Jun M,
    6. Patel A,
    7. Rodgers A,
    8. Thom S
    . The efficacy and tolerability of “polypills”: meta-analysis of randomised controlled trials. PLoS One 2012;7:e52145.
    OpenUrlCrossRefPubMed
  194. 194.↵
    1. Thom S,
    2. Poulter N,
    3. Field J,
    4. Patel A,
    5. Prabhakaran D,
    6. Stanton A,
    7. Grobbee DE,
    8. Bots ML,
    9. Reddy KS,
    10. Cidambi R,
    11. Bompoint S,
    12. Billot L,
    13. Rodgers A
    ; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918–929.
    OpenUrlCrossRefPubMed
  195. 195.↵
    1. Bautista LE,
    2. Vera-Cala LM,
    3. Ferrante D,
    4. et al
    . A “polypill” aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff. 2013;32:155–164.
    OpenUrlAbstract/FREE Full Text
  196. 196.↵
    1. Huffman MD,
    2. Yusuf S
    . Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol. 2014;63:1368–1370.
    OpenUrlCrossRef
  197. 197.↵
    1. Cameron A,
    2. Ewen M,
    3. Ross-Degnan D,
    4. Ball D,
    5. Laing R
    . Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373:240–249.
    OpenUrlCrossRefPubMed
  198. 198.↵
    1. Mendis S,
    2. Fukino K,
    3. Cameron A,
    4. Laing R,
    5. Filipe A Jr.,
    6. Khatib O,
    7. Leowski J,
    8. Ewen M
    . The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85:279–288.
    OpenUrlCrossRefPubMed
  199. 199.↵
    1. Vedanthan R,
    2. Fuster V
    . Urgent need for human resources to promote global cardiovascular health. Nat Rev Cardiol. 2011;8:114–117.
    OpenUrlCrossRefPubMed
  200. 200.↵
    1. van Olmen J,
    2. Schellevis F,
    3. Van Damme W,
    4. Kegels G,
    5. Rasschaert F
    . Management of chronic diseases in Sub-Saharan Africa: cross-fertilisation between HIV/AIDS and diabetes care. J Trop Med. 2012;2012:349312.
    OpenUrl
  201. 201.↵
    1. Frenk J
    . The global health system: strengthening national health systems as the next step for global progress. PLoS Med. 2010;7:e1000089.
    OpenUrlCrossRefPubMed
  202. 202.↵
    1. Ooms G,
    2. Van Damme W,
    3. Baker BK,
    4. Zeitz P,
    5. Schrecker T
    . The ‘diagonal’ approach to global fund financing: a cure for the broader malaise of health systems? Global Health. 2008;4:6.
    OpenUrlCrossRefPubMed
  203. 203.↵
    1. Samb B,
    2. Evans T,
    3. Dybul M,
    4. Atun R,
    5. Moatti J-P,
    6. Nishtar S,
    7. Wright A,
    8. Celletti F,
    9. Hsu J,
    10. Kim JY,
    11. Brugha R,
    12. Russell A,
    13. Etienne C
    . An assessment of interactions between global health initiatives and country health systems. Lancet. 2009;373:2137–2169.
    OpenUrlCrossRefPubMed
  204. 204.↵
    1. Drobac PC,
    2. Basinga P,
    3. Condo J,
    4. et al
    . Comprehensive and integrated district health systems strengthening: the Rwanda Population Health Implementation and Training (PHIT) partnership. BMC Health Serv Res. 2013;13(suppl 2):S5.
    OpenUrlCrossRef
  205. 205.↵
    1. Vasan A,
    2. Ellner A,
    3. Lawn SD,
    4. Gove S,
    5. Anatole M,
    6. Gupta N,
    7. Drobac P,
    8. Nicholson T,
    9. Seung K,
    10. Mabey DC,
    11. Farmer PE
    . Integrated care as a means to improve primary care delivery for adults and adolescents in the developing world: a critical analysis of Integrated Management of Adolescent and Adult Illness (IMAI). BMC Med. 2014;12:6.
    OpenUrlCrossRef
  206. 206.↵
    1. Mendis S,
    2. Fuster V
    . National policies and strategies for noncommunicable diseases. Nat Rev Cardiol. 2009;6:723–727.
    OpenUrlCrossRefPubMed
  207. 207.↵
    1. Narayan KM,
    2. Ali MK,
    3. Koplan JP
    . Global noncommunicable diseases–where worlds meet. N Engl J Med. 2010;363:1196–1198.
    OpenUrlCrossRefPubMed
  208. 208.↵
    1. Dieleman JL,
    2. Graves CM,
    3. Templin T,
    4. Johnson E,
    5. Baral R,
    6. Leach-Kemon K,
    7. Haakenstad AM,
    8. Murray CJL
    . Global health development assistance remained steady in 2013 but did not align with recipients’ disease burden. Health Aff (Millwood). 2014;33:878–886.
    OpenUrlAbstract/FREE Full Text
  209. 209.↵
    1. Stuckler D,
    2. King L,
    3. Robinson H,
    4. McKee M
    . WHO’s budgetary allocations and burden of disease: a comparative analysis. Lancet. 2008;372:1563–1569.
    OpenUrlCrossRefPubMed
  210. 210.↵
    1. Sridhar D,
    2. Batniji R
    . Misfinancing global health: a case for transparency in disbursements and decision making. Lancet. 2008;372:1185–1191.
    OpenUrlCrossRefPubMed
  211. 211.↵
    1. Nugent R,
    2. Feigl AB
    Where Have All the Donors Gone? Scarce Donor Funding for Non-Communicable Diseases. Center for Global Development: Washington, DC. 2010.
  212. 212.↵
    1. Sridhar D,
    2. Brolan CE,
    3. Durrani S,
    4. Edge J,
    5. Gostin LO,
    6. Hill P,
    7. McKee M
    . Recent shifts in global governance: implications for the response to non-communicable diseases. PLoS Med. 2013;10:e1001487.
    OpenUrlCrossRef
  213. 213.↵
    1. Vamadevan AS,
    2. Shah BR,
    3. Califf RM,
    4. Prabhakaran D
    . Cardiovascular research in India: a perspective. Am Heart J. 2011;161:431–438.
    OpenUrlCrossRefPubMed
  214. 214.↵
    1. Gurm HS,
    2. Eagle KA
    . Channelling regional registries for optimization of cardiac care: lessons from around the world. Eur Heart J. 2013;34:83–85.
    OpenUrlFREE Full Text
  215. 215.↵
    Global Burden of Metabolic Risk Factors of Chronic Diseases. http://www1.imperial.ac.uk/publichealth/departments/ebs/projects/eresh/majidezzati/healthmetrics/metabolicriskfactors/. Accessed February 26, 2014.
  216. 216.↵
    United Nations, Department of Economic and Social Affairs, Population Division (2013). World Population Prospects: The 2012 Revision, DVD Edition.
View Abstract

This Issue

Jump to

Article Tools

Share this Article

  • Email
  • Global Perspective on Acute Coronary Syndrome
    Rajesh Vedanthan, Benjamin Seligman and Valentin Fuster
    Circulation Research. 2014;114:1959-1975, originally published June 5, 2014
    https://doi.org/10.1161/CIRCRESAHA.114.302782
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects